The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...
Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...
The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
Pfizer (NYSE:PFE) said the FDA has approved its drug Hympavzi for the treatment of certain types of hemophilia. The agency ...
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...